IRIX

Business Context and Reporting Period

Company: IRIDEX Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: December 29, 2007
Business Overview: IRIDEX is a worldwide provider of therapeutic laser systems for ophthalmology (eye diseases) and aesthetics (skin conditions). The company operates two segments: Ophthalmology and Aesthetics. In January 2007, IRIDEX acquired the aesthetics business of Laserscope from American Medical Systems Holdings (AMS) to expand its product line. The company sells products directly in the U.S. and through approximately 100 independent distributors in 107 countries.

Key Financial Metrics

Note: 2007 results include a $2.5 million legal settlement gain from Synergetics and a $14.7 million impairment charge related to the Laserscope acquisition.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 54.6% to $55.5 million, driven primarily by the Laserscope acquisition which added $18.1 million in aesthetics revenue. Ophthalmology revenue grew modestly by 4.9%.
• Profitability Decline: The company swung from a net loss of $5.8 million in 2006 to a net loss of $22.3 million in 2007. This was primarily due to a $14.7 million impairment of goodwill and intangible assets and a 54.7% increase in Selling, General, and Administrative (SG&A) expenses.
• Gross Margin Compression: Gross margin decreased from 52.4% to 43.7%. This was caused by lower direct margins in the acquired aesthetics business, amortization of intangible assets ($1.8 million in COGS), and increased service costs.
• Liquidity Deterioration: Cash and cash equivalents dropped from $21.1 million to $5.8 million due to the acquisition costs and operating losses. Working capital declined significantly from $29.8 million to $7.7 million.
• Debt Assumption: The company incurred $9.9 million in debt (term loan and revolving credit) to fund the Laserscope acquisition, whereas it had no debt in 2006.

Guidance, Outlook, Risks, and Unusual Items

Going Concern Warning

The independent auditors (Burr, Pilger & Mayer LLP) issued an opinion stating there is substantial doubt about the company's ability to continue as a going concern. This is due to recurring losses, negative cash flows, and debt covenant compliance issues.

Debt Covenants and Liquidity

As of December 29, 2007, the company was out of compliance with debt covenants on its facilities with Mid-Peninsula Bank and the Export-Import Bank. A waiver was obtained, and subsequent to year-end, the company replaced these with a new $8 million asset-based revolving facility with Wells Fargo Bank. Management believes this provides sufficient liquidity for the next 12 months, but significant risk remains regarding the ability to meet covenants and pay obligations to AMS.

Acquisition Integration Risks

The company has not realized the anticipated benefits of the Laserscope acquisition. Integration has been expensive and difficult, resulting in a reduction of the domestic aesthetics sales force from 28 to 6 representatives. The company recorded a $14.7 million impairment charge on goodwill and intangibles related to this business unit.

Internal Controls

Management concluded that disclosure controls and procedures were not effective due to material weaknesses. These weaknesses stem from inadequate staffing in the finance function following the departure of the CFO and the demands of the acquisition, leading to failures in period-end review procedures.

Unusual Items

• Legal Settlement: Received $2.5 million in 2007 from Synergetics regarding patent litigation (total settlement $6.5 million over 5 years).
• AMS Obligations: The company has a remaining obligation of $4.8 million plus interest to AMS, plus $1.3 million in non-cancelable purchase orders for inventory.

Investor Verification Checklist

• Debt Covenant Compliance: Verify if the company has met the monthly net income and debt service coverage covenants under the new Wells Fargo facility.
• Cash Burn Rate: Monitor operating cash flow to ensure the company can meet the $4.8 million obligation to AMS and fund operations without further dilution or default.
• Remediation of Internal Controls: Confirm the hiring and effectiveness of the new CFO and additional finance staff to address the material weaknesses in financial reporting.
• Aesthetics Segment Performance: Assess whether the aesthetics business can achieve profitability and stabilize the sales force after the significant reduction in headcount.
• Inventory Levels: Review inventory balances ($16.0 million) relative to sales to ensure no further write-downs are necessary, given the $1.3 million in mandatory purchase orders from AMS.